Isolation of Adult Human Dermal Fibroblasts from Abdominal Skin and Generation of Induced Pluripotent Stem Cells Using a Non-Integrating Method
January 19th, 2020
10.8K views
Cell reprogramming requires the introduction of key genes, which regulate and maintain the pluripotent cell state. The protocol described enables the formation of induced pluripotent stem cells (iPSCs) colonies from human dermal fibroblasts without viral/integrating methods but using non-modified RNAs (NM-RNAs) combined with immune evasion factors reducing cellular defense mechanisms.
Overview
This protocol outlines the generation of autologous human-induced pluripotent stem cells (iPSCs) from human dermal fibroblasts. It utilizes non-modified RNAs and immune evasion factors to enhance reprogramming efficiency without viral methods.
Key Study Components
Area of Science
- Cell Reprogramming
- Stem Cell Biology
- Regenerative Medicine
Background
- iPSCs are crucial for regenerative medicine and disease modeling.
- Traditional methods often involve viral integration, which can pose risks.
- This protocol aims to provide a safer, non-viral approach.
- Understanding the reprogramming process is essential for effective application.
Purpose of Study
- To develop a protocol for generating iPSCs from dermal fibroblasts.
- To facilitate research in regenerative medicine and disease modeling.
- To provide a method accessible to researchers with limited experience.
Methods Used
- Isolation of human dermal fibroblasts from skin punch biopsies.
- Application of non-modified RNAs for reprogramming.
- Incorporation of immune evasion factors to reduce cellular defenses.
- Visual demonstrations to aid in the protocol execution.
Main Results
- Successful generation of xeno-free iPSC colonies.
- Protocol allows for efficient reprogramming with minimal contamination risks.
- Autologous iPSCs can be utilized for various applications.
- Guidance provided to avoid common experimental mistakes.
Conclusions
- The protocol offers a reliable method for generating iPSCs.
- It supports advancements in regenerative medicine and disease research.
- Accessible to researchers with varying levels of experience.
Frequently Asked Questions
What are induced pluripotent stem cells (iPSCs)?
iPSCs are stem cells that can be generated directly from adult cells and have the ability to differentiate into any cell type.
Why is a non-viral method preferred for reprogramming?
Non-viral methods reduce the risk of insertional mutagenesis and other complications associated with viral vectors.
What is the significance of using autologous cells?
Autologous cells minimize the risk of immune rejection and enhance the compatibility of the stem cells for therapeutic applications.
How can iPSCs be used in disease modeling?
iPSCs can be differentiated into specific cell types to study disease mechanisms and test potential therapies in a laboratory setting.
What precautions should be taken during the reprogramming process?
It is essential to prevent microbial contamination and ensure the integrity of RNA used in the reprogramming process.
Executive Industry Relevance
This protocol enables the generation of xeno-free, autologous human iPSCs from abdominal dermal fibroblasts using a non-integrating RNA-based method, addressing key safety and scalability barriers in regenerative medicine and disease modeling. By avoiding viral vectors and animal-derived components, it reduces genomic instability and immunogenicity risks, supporting downstream applications in target validation, phenotypic screening, and preclinical de-risking. The method’s accessibility to researchers with limited reprogramming experience enhances its utility as a reproducible, enterprise-ready tool for early-stage discovery workflows.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses through generation of genetically matched human iPSCs for pathway clarification and functional target validation.
- Operational Value: Supports biological de-risking by providing a renewable, patient-derived cellular system to assess target engagement and mechanism of action.
- Predictive Value: Facilitates portfolio triage by allowing early assessment of target modulation in a disease-relevant human cellular context.
Screening & Assay Development
- Assay Readiness: Produces standardized, passage-controlled iPSC populations suitable for downstream differentiation into disease-relevant cell types for screening applications.
- Reproducibility: Defined culture conditions and xeno-free environment enhance assay consistency and reduce variability in compound response readouts.
- Scalability: Protocol supports expansion of fibroblast-derived iPSCs in multi-well formats, enabling medium-to-high throughput screening campaigns.
Translational & Preclinical Research
- Disease Modeling: Autologous iPSCs derived from abdominal skin fibroblasts can be differentiated into lineages relevant to genetic disorders, cancer, or degenerative diseases for mechanistic studies.
- Preclinical Continuity: Enables seamless transition from discovery to preclinical validation by providing a human cellular system that maintains genetic fidelity of the donor.
- Risk-Adjusted Advancement: Supports go/no-go decisions by allowing evaluation of target modulation and phenotypic rescue in clinically relevant human models prior to in vivo testing.
Pipeline & Workflow Integration
The method fits within the discovery continuum from early target validation through lead identification to preclinical evaluation, providing a renewable human cellular platform that bridges in vitro findings with translational relevance.
- Discovery Biology: Supports hypothesis testing and pathway clarification by enabling generation of iPSCs that retain donor-specific genetic background for target de-risking.
- Screening: Delivers assay-ready, passage-defined iPSCs that can be differentiated into uniform cell populations for reliable compound screening and target engagement assays.
- Analytics: Generates quantitative, measurable outputs such as colony formation kinetics, pluripotency marker expression, and differentiation efficiency to inform decision-making.
- Translational Research: Connects discovery to preclinical work by providing autologous, xeno-free iPSCs capable of differentiating into disease-relevant cell types for mechanism-of-action and safety profiling.
- Enterprise Reuse: Establishes a reusable, standardized pipeline for iPSC generation that can be applied across multiple projects and therapeutic areas, reducing redundant development effort.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence by reducing mechanistic ambiguity through use of genetically matched, human-derived iPSCs in functional assays.
- Operational Value: Promotes standardization and reproducibility via defined, xeno-free culture conditions and non-integrating reprogramming that minimizes batch variability.
- Strategic Value: Improves capital efficiency and reduces late-stage failure risk by enabling early detection of target-related toxicities or lack of efficacy in human cellular models.
- Portfolio Impact: Supports risk-adjusted prioritization by generating data on target modulation in human cells that informs advancement decisions with greater translational confidence.
Implementation Considerations
- Requires expertise in cell culture, sterile technique, and RNA handling to prevent contamination and ensure reprogramming efficiency.
- Dependent on access to inverted phase contrast microscopes, hemocytometers, and sterile hoods for fibroblast isolation, transfection, and colony monitoring.
- Necessitates standardization of transfection timing, reagent volumes, and passaging schedules across teams to maintain consistent iPSC quality.
- Requires adaptation of plating density and medium formulations based on donor-specific fibroblast proliferation rates observed during expansion.
- Practical limitation: Reprogramming efficiency is influenced by cell passage number and confluence, necessitating careful monitoring of fibroblast quality prior to transfection.
Biopharma FAQs
Why does non-integrating reprogramming reduce genomic instability risk?
The protocol uses non-modified RNAs that do not integrate into the host genome, avoiding insertional mutagenesis associated with viral vectors. This preserves genomic integrity of the resulting iPSCs, which is critical for clinical safety and regulatory compliance in regenerative medicine applications.
How does fibroblast synchronization improve reprogramming efficiency?
Synchronizing fibroblasts via S-DMEM treatment for 48 hours prior to transfection aligns the cell cycle, enhancing susceptibility to RNA transfection and improving reprogramming consistency. This step reduces variability in colony formation timing and increases the yield of early iPSC colonies.
What quantitative measurements enable iPSC colony assessment?
Colony formation is monitored daily using phase contrast microscopy, with metrics including colony size, number, and morphology tracked from day 1 to day 14 post-transfection. These readouts allow researchers to evaluate reprogramming kinetics and stability over time, informing optimization of transfection schedules.
Why are replication requirements important for iPSC line validation?
Repeating the transfection procedure over four consecutive days ensures stable reprogramming and reduces the likelihood of transient or incomplete pluripotency. This multi-day approach supports the generation of robust, fully reprogrammed iPSC colonies suitable for downstream expansion and differentiation.
What statistical analysis is needed before implementing this protocol in screening?
Prior to screening, researchers should analyze transfection efficiency, colony formation rates, and pluripotency marker expression across replicates to establish baseline reproducibility. This statistical evaluation ensures the iPSC generation process is sufficiently robust and consistent for use in assay development and compound screening campaigns.
